Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring dmd mutations

Stem Cells and Development

Volumn 22, Issue 20, 2013, Pages 2714-2724

  Dick, Emily ^a   Kalra, Spandan ^a   Anderson, David ^a   George, Vinoj ^a   Ritso, Morten ^b   Laval, Steven H ^b   Barresi, Rita ^c   Aartsma Rus, Annemieke ^d   Lochmüller, Hanns ^b   Denning, Chris ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE DENTAL HOSPITAL   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENE DELETION; GENE TRANSFER; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MYOBLAST; MYOTUBE; PLURIPOTENT STEM CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCH BIOPSY; SINGLE CELL ANALYSIS;

BASE SEQUENCE; CELL DIFFERENTIATION; CHILD; DYSTROPHIN; EXONS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MOLECULAR SEQUENCE DATA; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; MYOCYTES, CARDIAC; OLIGONUCLEOTIDES, ANTISENSE; PRIMARY CELL CULTURE;

EID: 84885133772     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0135     Document Type: Article

References (34)

1. Aartsma-Rus A, JT den Dunnen and GJ van Ommen. (2010). New insights in gene-derived therapy: The example of Duchenne muscular dystrophy. Ann N Y Acad Sci 1214:99-212
2. Rando TA. (2001). The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24:1575-1594
3. Strober JB. (2006). Therapeutics in duchenne muscular dystrophy. NeuroRx 3:225-234
4. Wood MJ, MJ Gait and H Yin. (2010). RNA-targeted splicecorrection therapy for neuromuscular disease. Brain 133(Pt 4):957-972
5. Sugita H and S Takeda. (2010). Progress in muscular dystrophy research with special emphasis on gene therapy. Proc Jpn Acad Ser 86:748-756
6. Aartsma-Rus A. (2010). Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy. RNA Biol 7:453-461
7. Cirak S, V Arechavala-Gomeza, M Guglieri, L Feng, S Torelli, K Anthony, S Abbs, ME Garralda, J Bourke, et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 378:595-605
8. Goemans NM, M Tulinius, JT van den Akker, BE Burm, PF Ekhart, N Heuvelmans, T Holling, AA Janson, GJ Platenburg, et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364:1513-1522
9. Aartsma-Rus A, I Fokkema, JJ Verschuuren, HB Ginjaar, JCT van Deutekom, GJB van Ommen and JT den Dunnen. (2009). Applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30:293- 299
10. Malerba A, L Boldrin and G Dickson. (2011). Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: Implications for cardiac muscle integrity. Nucleic Acid Ther 21:293-298
11. Aartsma-Rus A, AA Janson, WE Kaman, M Bremmer-Bout, JT den Dunnen, F Baas, GJ van Ommen and JC van Deutekom. (2003). Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12:907-914
12. Lu QL, T Yokota, S Takeda, L Garcia, F Muntoni and T Partridge. (2011). The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Mol Ther 19:9-15
13. Heemskerk H, C de Winter, P van Kuik, N Heuvelmans, P Sabatelli, P Rimessi, P Braghetta, GJ van Ommen, S de Kimpe, et al. (2010). Preclinical PK and PD studies on 2¢-Omethyl- phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 18:1210-1217
14. Matsa E, D Rajamohan, E Dick, L Young, I Mellor, A Staniforth and C Denning. (2011). Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 32:952-962
15. Dick E, E Matsa, J Bispham, M Reza, M Guglieri, A Staniforth, S Watson, R Kumari, H Lochmüller, et al. (2011). Two new protocols to enhance the production and isolation of human induced pluripotent stem cell lines. Stem Cell Res 6:158-167
16. Dick E, E Matsa, LE Young, D Darling and C Denning. (2011). Faster generation of hiPSCs by coupling high-titer lentivirus and column-based positive selection. Nat Protoc 6:701-714
17. Anderson D, T Self, IR Mellor, G Goh, SJ Hill and C Denning. (2007). Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol Ther 15:2027-2036
18. Burridge PW, D Anderson, H Priddle, MD Barbadillo Muñoz, S Chamberlain, C Allegrucci, LE Young and C Denning. (2007). Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells 25:929-938
19. Dick EP, E Matsa, J Bispham, M Reza, M Guglieri, A Staniforth, S Watson, R Kumari, H Lochmüller, et al. (2011). Two new protocols to enhance the production and isolation of human induced pluripotent stem cell lines. Stem Cell Res 6:158
20. Yu J, MA Vodyanik, K Smuga-Otto, J Antosiewicz-Bourget, JL Frane, S Tian, J Nie, GA Jonsdottir, V Ruotti, et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920
21. Maherali N and K Hochedlinger. (2008). Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 3:595-605
22. Chin MH, M Pellegrini, K Plath and WE Lowry. (2010). Molecular analyses of human induced pluripotent stem cells and embryonic stem cells. Cell Stem Cell 7:263-269
23. Aartsma-Rus A, JCT van Deutekom, IF Fokkema, GJC van Ommen and JT den Dunnen. (2006). Entries in the Leiden DMD mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34:135-144
24. Aartsma-Rus A, WE Kamen, M Bremmer-Bout, A Janson, JT Den Dunnen, GJB van Ommen and JCT van Deutekom. (2004). Comparative analysis of antisense oligonucleotides analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 11:1391-1398
25. Neri M, S Torelli, S Brown, I Ugo, P Sabatelli, L Merlini, P Spitali, P Rimessi, F Gualandi, et al. (2007). Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord 17:913-918
26. Muntoni F, S Torelli and A Ferlini. (2003). Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol 2:731-740
27. Denti MA, T Incitti, O Sthandier, C Nicoletti, FG De Angelis and E Rizzuto. (2008). Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther 19:601-608
28. Goyenvalle A, A Vulin, F Fougerousse, F Leturcq, JC Kaplan, L Garcia and O Danos. (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science 306:1796-1799
29. Yin H, AF Saleh, C Betts, P Camelliti, Y Seow, S Ashraf, A Arzumanov, S Hammond, T Merritt, MJ Gait and MJ Wood. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide- mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19:1295- 1303
30. Ezzat K, SE Andaloussi, EM Zaghloul, T Lehto, S Lindberg, PM Moreno, JR Viola, T Magdy, R Abdo, et al. (2011). PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res 39:5284-5298
31. van Deutekom JC, M Bremmer-Bout, AA Janson, IB Ginjaar, F Baas, JT den Dunnen and GJ van Ommen. (2001). Antisense- induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 10:1547-1554
32. Dick E, D Rajamohan, J Ronksley and C Denning. (2010). Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans 38:1037-1045
33. Földes G, M Mioulane, JS Wright, AQ Liu, P Novak, B Merkely, J Gorelik, MD Schneider, NN Ali and SE Harding. (2011). Modulation of human embryonic stem cell-derived cardiomyocyte growth: A testbed for studying human cardiac hypertrophy? J Mol Cell Cardiol 50:367-376
34. Cowan CA, I Klimanskaya, J McMahon, J Atienza, J Witmyer, JP Zucker, S Wang, CC Morton, AP McMahon, D Powers and DA Melton. (2004). Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med 350:1353-1356